NCT05676450
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
StatusRecruiting
PhaseNot applicable
SponsorM.D. Anderson Cancer Center
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 8 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2028
- Eligibility criteria expanded, about 5 words
- Study description expanded, about 2 words
- Minor Site contacts updated at 1 of 2 sitesv10
- Minor Site contacts updated at 2 of 2 sitesv8
- Notable Primary completion date: Aug 31, 2024 to Aug 31, 2026
- Site contacts updated at 2 of 2 sites
- Minor Study sites: 1 to 2v5
Show 2 earlier versionsHide 2 earlier versions
- Minor Start date: Feb 2, 2023 to Feb 23, 2023v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study completion date: Aug 31, 2024 to Aug 31, 2026
- Start date changed from estimate of May 1, 2023 to Feb 2, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall Survival (OS)
Timeframe: through study completion; an average 1 year
Arms and interventions
cell-free DNA (cfDNA) samplesOther
cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method. Blood will be drawn 3 times (by vein)
Diagnostic tests: cell-free DNA
Sites
2 sites in 1 country